Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finances
Bridge financing for phase 2 trial on blood substitute set, phase 3 funds sought
December 12th, 2004
Synthetic Blood International, Inc. (SYBD) has received bridge financing from overseas investors that is expected to be sufficient to fund operations, including the initiation of the company's first phase 2 Oxycyte trial, through mid-first quarter of calendar 2005. Oxycyte is the company's proprietary perfluorocarbon blood substitute and therapeutic oxygen carrier. The amount in terms of the financing was not disclosed. The company also announced this it is currently negotiating terms for an additional financing through U.S.-based institutional investors, which will be sufficient to fund the company's clinical program through the initiation of...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
